Vaxcyte VAX-31 Phase 3 Trial Meets All Primary Endpoints
Vaxcyte reported positive topline Phase 3 OPUS-1 results for VAX-31, meeting all prespecified immunogenicity and safety endpoints versus PCV20/PCV21.
Key Highlights:Original SEC Filing: Vaxcyte, Inc. [ PCVX ] - 8-K - Oct. 05, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider v…